Harbour Investments Inc. increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 172.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,521 shares of the biopharmaceutical company’s stock after buying an additional 12,365 shares during the period. Harbour Investments Inc.’s holdings in Gilead Sciences were worth $2,396,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Paulson Wealth Management Inc. increased its stake in shares of Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after buying an additional 67 shares during the last quarter. Alpha Cubed Investments LLC increased its stake in shares of Gilead Sciences by 1.1% in the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after buying an additional 75 shares during the last quarter. Personal CFO Solutions LLC increased its stake in shares of Gilead Sciences by 1.7% in the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 76 shares during the last quarter. Moss Adams Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 1.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after buying an additional 76 shares during the last quarter. Finally, Valued Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 12.5% in the fourth quarter. Valued Wealth Advisors LLC now owns 711 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 79 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.
Insider Buying and Selling
In related news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This represents a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the sale, the chief executive officer directly owned 632,567 shares of the company’s stock, valued at $81,702,353.72. The trade was a 1.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 63,000 shares of company stock valued at $8,523,570 over the last 90 days. 0.30% of the stock is currently owned by company insiders.
Gilead Sciences Stock Down 0.0%
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.
Gilead Sciences Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is presently 44.69%.
Wall Street Analysts Forecast Growth
GILD has been the subject of several recent research reports. Wall Street Zen lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Wednesday, May 20th. Argus boosted their target price on shares of Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Daiwa Securities Group lowered their target price on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, May 19th. Finally, Oppenheimer boosted their target price on shares of Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a research note on Wednesday, February 11th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $156.93.
Check Out Our Latest Stock Report on GILD
Gilead Sciences Company Profile
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Featured Stories
- Five stocks we like better than Gilead Sciences
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
